Pharmafile Logo

Inizio Engage CEO Jim Sage featured in pharmaphorum’s “12 Questions” series

December 11, 2025 | Pharmaphorum 

Discover Jim Sage’s insights on leadership, industry challenges, and the transformative impact of data, technology, and patient-centric innovation in his latest pharmaphorum “12 Questions” interview.

- PMLiVE

We’re pleased to share that Jim Sage, Global CEO and President of Inizio Engage, has been featured in pharmaphorum’s latest “12 Questions” interview series.

In the conversation, Jim reflects on his career across international markets, his motivations as a leader, and the experiences that have shaped his approach to building high-performing teams. He also explores some of the most pressing challenges facing the pharmaceutical industry today, including pricing pressures, launch performance, and the need for new reimbursement models.

Jim highlights how data, technology, and AI are already transforming the way organisations operate, and discusses the growing importance of patient-centric approaches, from HUB services to personalised support throughout the treatment journey.

Read the full interview on pharmaphorum.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Biosimilars: Bringing patients into the conversation

Published in eyeforpharma January 2017 by Mariel Metcalfe

Access and elimination: the future of DAAs in hepatitis C

Published in Pharmaphorum January 2017

EphMRA One Day Meeting

We are delighted to be attending and presenting a paper at the EphMRA one day meeting on Tuesday 21st February, in London

Video: Segmentation research

Why would a pharma company want to carry out a segmentation study? What are some of the challenges? Head of Business Analytics Tom Nolte and Associate Director Dr Marianne Jaeger...

Pharmaceutical Market Research Conference 2017

We are delighted to be exhibiting and presenting a paper at the Pharmaceutical Market Research Conference 1-2 February in Parsippany, NJ.

Shifting perceptions of the use of probiotics in IBS Management

Our client was planning to launch an over-the-counter (OTC) probiotics product for the purposes of improving IBS management and wanted to understand current perceptions, practices and usage amoungst a range...

Nutraceuticals in India: A Challenging Opportunity

Published in eyeforpharma December 2016 by Marc Yates

Research Partnership makes annual donation to Forever Projects

Research Partnership has made a seasonal donation of US$5,000 to our chosen charity, Forever Projects

A Bitter Pill?

The ideal route of admin isn’t clear cut in the global marketplace

Understanding the chronic disease patient journey in emerging markets

In this paper, we will explore the chronic disease patient journey in emerging markets and provide you with the insights you require to identify the key inflection points in these...